<DOC>
	<DOC>NCT00290940</DOC>
	<brief_summary>This study will compare glucose lowering with CS-917 compared to placebo after 3 months of treatment</brief_summary>
	<brief_title>Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Drug naive or newly diagnosed type 2 diabetic subjects: Never received oral antihyperglycemic or insulin therapy or No oral antihyperglycemic or insulin therapy for more than 6 months since original diagnosis and No insulin therapy within one year of screening, with the exception of use during hospitalization or for use in gestational diabetes and No antihyperglycemic therapy for more than three consecutive days, or a total of of seven nonconsecutive days, during the 8 weeks prior to screening. HbA1C&gt;6.7% and &lt; or = to 10% at screening Current insulin therapy Symptoms of poorly controlled diabetes History of diabetic ketoacidosis or hyperosmolar, nonketonic coma within one year of screening Serum bicarbonate &lt; or = to 19 meq/L Serum creatinine (Scr) &gt; 1.4 mg/dL (females) or 1.5 mg/dL (males) Contraindication to metformin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Diabetes mellitus, Type 2</keyword>
	<keyword>High blood sugar</keyword>
	<keyword>Hyperglycemia</keyword>
	<keyword>Antihyperglycemic agents</keyword>
	<keyword>CS-917</keyword>
</DOC>